Edgewise Therapeutics (EWTX) director Martin received 45,150 Stock Options (Right to buy)
Insider transactions reported
Christopher Nathan Martin (director at Edgewise Therapeutics Inc., EWTX) reported that they received 45,150 Stock Options (Right to buy) on Nov 19, 2025.
- Reporting person
- Martin Christopher Nathan
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Nov 19, 2025 | Grant or award (A) | Stock Options (Right to buy)On 45,150 Common Stock1 | +45,150 | - | - | 45,150 direct |
Holdings before and after
- Stock Options (Right to buy): 0 to 45,150 direct
Footnotes from the filing
- 1. 1/36th of the shares subject to the option vest each month beginning on December 19, 2025, subject to the Reporting Person continuing as a service provider through each vest date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Martin report in this EWTX Form 4?
Christopher Nathan Martin (director at Edgewise Therapeutics Inc., EWTX) reported that they received 45,150 Stock Options (Right to buy) on Nov 19, 2025.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for EWTX
Across the 6 sessions after earlier EWTX headlines, the stock closed higher 2 times and lower 4 times, with a median move of 1.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | EWTX | SPY |
|---|---|---|---|
| Nov 20, 2025 | Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors | -0.4% | -1.5% |
| Nov 12, 2025 | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | -1.4% | +0.1% |
| Nov 10, 2025 | Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers | +6.5% | +1.6% |
| Nov 7, 2025 | Edgewise Therapeutics to Participate in Upcoming Investor Conferences | +0.4% | +0.1% |
| Nov 6, 2025 | Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | -1.6% | -1.1% |
| Nov 3, 2025 | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | -1.7% | +0.2% |
Earlier insider filings at EWTX
- Nov 13, 2025Chief Scientific Officer Russell Alan J exercised 100,000 shares at a strike of $0.18 and sold $2,112,450 worth of shares (100,000 units at $21.12) (SEC Form 4)
- Nov 13, 2025Director Fox Jonathan C bought $199,403 worth of shares (10,700 units at $18.64), increasing direct ownership by 82% to 23,702 units (SEC Form 4)
- Nov 13, 2025SEC Form 4 filed by Chief Financial Officer Nofi Michael
- Oct 3, 2025Director Fox Jonathan C was granted 728 shares, increasing direct ownership by 6% to 13,002 units (SEC Form 4)
- Aug 28, 2025Chief Scientific Officer Russell Alan J exercised 100,000 shares at a strike of $0.18 and sold $1,459,760 worth of shares (100,000 units at $14.60) (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Follow EWTX and get a push notification the moment its next story breaks.